UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nivolumab (1065) 1065
science & technology (1037) 1037
life sciences & biomedicine (1026) 1026
humans (844) 844
oncology (645) 645
immunotherapy (577) 577
melanoma (429) 429
male (421) 421
female (372) 372
metastasis (363) 363
middle aged (355) 355
aged (334) 334
pembrolizumab (327) 327
patients (324) 324
ipilimumab (317) 317
lung cancer (287) 287
chemotherapy (270) 270
cancer therapies (266) 266
cancer (264) 264
care and treatment (242) 242
lung neoplasms - drug therapy (223) 223
programmed cell death 1 receptor - antagonists & inhibitors (223) 223
antibodies, monoclonal - therapeutic use (209) 209
nivolumab - therapeutic use (206) 206
melanoma - drug therapy (200) 200
treatment outcome (200) 200
tumors (195) 195
nivolumab - adverse effects (189) 189
nivolumab - administration & dosage (186) 186
adult (183) 183
antineoplastic agents, immunological - adverse effects (182) 182
case report (182) 182
antineoplastic agents, immunological - therapeutic use (181) 181
apoptosis (175) 175
immune checkpoint (175) 175
immunology (173) 173
antibodies, monoclonal - adverse effects (165) 165
clinical trials (164) 164
antineoplastic agents - therapeutic use (154) 154
antineoplastic combined chemotherapy protocols - therapeutic use (150) 150
drug therapy (150) 150
carcinoma, non-small-cell lung - drug therapy (146) 146
lymphocytes (146) 146
metastases (139) 139
aged, 80 and over (138) 138
pd-1 (136) 136
antibodies, monoclonal - administration & dosage (134) 134
neoplasms. tumors. oncology. including cancer and carcinogens (133) 133
antineoplastic agents, immunological - administration & dosage (129) 129
research (122) 122
immunotherapy - methods (116) 116
medical prognosis (114) 114
antineoplastic agents - adverse effects (111) 111
cytotoxicity (111) 111
lung cancer, non-small cell (111) 111
medicine & public health (108) 108
programmed cell death 1 receptor - immunology (105) 105
pd-1 protein (104) 104
analysis (103) 103
melanoma - pathology (100) 100
skin neoplasms - drug therapy (100) 100
mutation (99) 99
pharmacology & pharmacy (97) 97
ligands (96) 96
lung neoplasms - pathology (96) 96
antibodies, monoclonal, humanized - therapeutic use (95) 95
antigens (95) 95
prognosis (94) 94
immune checkpoint inhibitor (89) 89
biomarkers (88) 88
development and progression (87) 87
cell death (85) 85
retrospective studies (85) 85
dermatology (84) 84
antineoplastic combined chemotherapy protocols - adverse effects (83) 83
immune checkpoint inhibitors (83) 83
immune system (83) 83
non-small cell lung carcinoma (83) 83
health aspects (82) 82
non-small cell lung cancer (81) 81
skin cancer (81) 81
pd-l1 (80) 80
monoclonal antibodies (79) 79
medical research (77) 77
usage (74) 74
b7-h1 antigen - antagonists & inhibitors (73) 73
fda approval (73) 73
general & internal medicine (73) 73
ctla-4 antigen - antagonists & inhibitors (72) 72
neoplasm metastasis (72) 72
neoplasm staging (72) 72
immunoglobulins (70) 70
ipilimumab - administration & dosage (70) 70
lymphocytes t (69) 69
medicine, general & internal (69) 69
radiation therapy (69) 69
atezolizumab (68) 68
ipilimumab - adverse effects (68) 68
antibodies (66) 66
complications and side effects (66) 66
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1336) 1336
Japanese (13) 13
French (7) 7
German (4) 4
Russian (3) 3
Korean (2) 2
Norwegian (2) 2
Danish (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 02/2018, Volume 36, Issue 4, pp. 383 - 390
Journal Article
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2016, Volume 27, Issue 12, pp. 2242 - 2250
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue S11, pp. 2130 - 2142
Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration... 
neoantigen | targeted therapy | B‐Raf proto‐oncogene serine/threonine kinase (BRAF) | catenin‐β 1 (CTNNB1) | immunotherapy | combination therapy | melanoma | phosphatase and tensin homolog (PTEN) | neuroblastoma rat sarcoma viral oncogene homolog (NRAS) | guanosine‐triphosphate guanyltransferase (GTPase) | personalized medicine | catenin-β 1 (CTNNB1) | B-Raf proto-oncogene serine/threonine kinase (BRAF) | guanosine-triphosphate guanyltransferase (GTPase) | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Tumor Escape - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Ipilimumab | Wnt Signaling Pathway - immunology | Oximes - administration & dosage | Imidazoles - administration & dosage | Drug Resistance, Neoplasm | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Molecular Targeted Therapy | Indoles - administration & dosage | MAP Kinase Kinase 1 - genetics | Pyridones - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | PTEN Phosphohydrolase - immunology | Melanoma - genetics | Immunotherapy | Tumor Escape - immunology | MAP Kinase Kinase 1 - antagonists & inhibitors | PTEN Phosphohydrolase - genetics | Skin Neoplasms - immunology | Membrane Proteins - genetics | GTP Phosphohydrolases - immunology | Membrane Proteins - immunology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Wnt Signaling Pathway - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Melanoma - immunology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Nivolumab | Proto-Oncogene Proteins B-raf - immunology | Skin Neoplasms - genetics | Pyrimidinones - administration & dosage | Mutation | CTLA-4 Antigen - antagonists & inhibitors | Sulfonamides - administration & dosage | Medical research | Translation | Immune response | Melanoma | Clinical trials | Patients | Immunity | Disease resistance | Alterations | Molecular modelling | Correlation analysis | Biomarkers | Cancer | Immune system | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 11/2018, Volume 19, Issue 11, pp. 1480 - 1492
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2017, Volume 377, Issue 14, pp. 1345 - 1356
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 12/2017, Volume 35, Issue 34, pp. 3807 - 3814
Journal Article